1. Use of a 1-aminoalkylcyclohexane derivative for the treatment or prevention of tinnitus associated with hearing loss or minor hearing loss. 2. The use according to claim 1, wherein the 1-aminoalkylcyclohexane derivative is neramexane or a pharmaceutically acceptable salt thereof. The use according to claim 2, wherein the 1-aminoalkylcyclohexane derivative is neramexane mesylate. The use according to claim 3, where neramexane mesylate is administered in the range of from about 5 to about 150 mg per day, or neramexane mesylate is administered in the range of from about 5 to about 100 mg per day, or neramexane mesylate is administered in the range of from about 5 mg to about 75 mg per day, or neramexane mesylate is administered at a dose of 50 mg per day, or neramexane mesylate is administered at a dose of about 75 mg per day. 5. The use according to claim 2, wherein neramexane or a pharmaceutically acceptable salt thereof is administered once a day, twice a day (b.i.d.) or three times a day. The use of claim 5, wherein neramexane or a pharmaceutically acceptable salt thereof is administered twice daily. The use according to claim 2, wherein neramexane or a pharmaceutically acceptable salt thereof is administered in an immediate release dosage form or in a modified release dosage form. The use of claim 1, wherein an additional pharmaceutical agent effective for treating or preventing tinnitus is administered, and optionally at least one pharmaceutically acceptable carrier or excipient. The use according to claim 1, wherein an additional pharmaceutical agent selected from antidepressants or anti-anxiety agents, dopamine antagonists, alpha2delta ligands and NK1 antagonists is administered, and optionally,1. Применение производного 1-аминоалкилциклогексана для лечения или предупреждения шума в ушах, связанного с потерей слуха или с незначительной потерей слуха.2. Применение по п.1, где производное 1-аминоалкилциклогексана представляет собой нерамексан или его фармацевт
